BioSpace News Archive

According to the most recent estimate by Emergen Research, the global digital health market will be worth USD 175.20 billion in 2021 and grow at a revenue CAGR of 27.2% throughout the projected period.

According to Vision Research Reports, the rare disease genetic testing market was valued at USD 785.95 million in 2021 and it is predicted to surpass around USD 2.77 billion by 2030 with a CAGR of 15.02% from 2022 to 2030.

The global Stem Cells market size is expected to be worth around US$ 28.4 billion by 2030, according to a new report by Vision Research Reports.

According to Vision Research Reports, the rare diseases treatment market was surpassed at USD 119.71 billion in 2021 and is expected to hit around USD 335.99 billion by 2030, growing at a CAGR of 12.15% from 2022 to 2030

Sight Sciences, Inc., an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients’ lives, announced plans to present at the upcoming Inaugural Gilmartin Group Emerging Growth Company Showcase, taking place virtually.

Viridian Therapeutics, Inc. announced that it has issued an additional 1,725,000 shares of common stock at a public offering price of $23.50 per share, resulting in additional gross proceeds of approximately $40.5 million, pursuant to the exercise in full of the underwriters’ option to purchase additional shares of common stock in connection with the Company’s previously announced public offering of common stock and Series B Preferred Stock.

Vaxart, Inc. announced that Elaine J. Heron, Ph.D. was appointed to the Company’s Board of Directors, effective August 25, 2022.

Regeneron Pharmaceuticals, Inc. will webcast management participation as follows.